Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns
NCT ID: NCT07326657
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE4
65 participants
INTERVENTIONAL
2026-01-31
2029-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Difference in the percentage area of the IFSG treatment site and control autograft treatment site that required autografting within 1 month of treatment
2. Proportion of subjects achieving durable wound closure of the IFSG treatment site without autograft placement within 2 months of treatment
3. Difference in cosmesis between the IFSG treatment site and autograft treatment site a year after treatment
4. Difference in the pain intensity between the IFSG treatment site and autograft treatment site
Each participant will receive autograft and intact fish skin graft (IFSG) on different areas of their deep partial-thickness burn. Participants will be assessed for the need for further autograft treatment. Participants will also be assessed for wound closure, pain, and cosmesis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns
NCT03984331
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
NCT03005106
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
NCT01437852
Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds
NCT01655407
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
NCT03227146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IFSG-Treated Area of Burn
The area of the deep partial-thickness burn that is treated with IFSG
Intact fish skin graft
Treatment with IFSG
SOC Autograft-Treated Area of Burn
The area of the deep partial-thickness burn that is treated with autograft as standard-of-care
autograft
Treatment with autograft
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intact fish skin graft
Treatment with IFSG
autograft
Treatment with autograft
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated.
3. Be able to provide written informed consent or have a legally authorized representative
4. Have sufficient healthy skin identified and designated as a potential donor site in the event that the IFSG treatment site requires autografting.
5. Investigator expects that the donor site will heal without grafting
6. Have a complex skin defect of 3 to 49% Total Body Surface Area, which can consist of more than one contiguous area
At the time of debridement:
7. Have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated
8. Study treatment areas can be up to 2000 cm2
9. Must have at least 100 cm2 TBSA for which autografting is indicated and on which IFSG can be applied, which may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso
10. Application of IFSG or SOC must be initiated within 14 days of injury (Application of IFSG or SOC must be initiated within 14 days of injury)
11. Have first excision and grafting of study treatment sites
12. Have thermal burn(s) on the torso or extremities
Exclusion Criteria
2. Female who is actively pregnant or currently breast-feeding
3. Vulnerable populations
4. Currently receiving systemic immunosuppressive therapy
5. Current or known history of malignancy or receipt of chemotherapy
6. History of Diabetes with documented uncontrolled diabetes (as defined by an A1C \>9) within the last 6 months
7. Have an expected survival of less than 3 months
8. Are currently participating/have participated in the treatment group of an interventional study within 90 calendar days prior to consent
9. Have other wounds present for \> 30 days
At the time of debridement:
10. Treatment area is assessed as full-thickness after debridement
11. Treatment areas on the face, neck, head, hands, feet, buttocks, perineum, and areas over joints (Treatment areas may only be on the torso or extremities)
12. Have a clinical or laboratory determination of infection at the anticipated treatment sites.
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Burn Association
OTHER
BData, Inc.
UNKNOWN
Kerecis Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loyola University Medical Center
Maywood, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KS-1040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.